Prostate cancer screening - is it time to change approach?

• Published in: Central European journal of public health Vol. 30; no. Supplement; pp. S11 - S15
• Main Authors: Vargovčák, Marek, Dorko, Erik, Rimárová, Kvetoslava, Knap, Viliam
• Format: Journal Article
• Language: English
• Published: Prague National Institute of Public Health 01-06-2022
• Subjects: Adenocarcinoma; Age groups; Antigens; Asymptomatic; Biopsy; Cancer screening; Comorbidity; Diagnosis; Disease prevention; Documentation; Epidemiology; Evaluation; Family medical history; Health insurance; Hyperplasia; Medical screening; Metastases; Mortality; Outpatient care facilities; Patients; Population; Population studies; Prostate cancer; Prostatitis; Quality of life; Rectum; Risk assessment; Risk groups; Tumors; Ultrasonic imaging; Urology; United States > US; Slovakia
• ISSN: 1210-7778; 1803-1048
• DOI: 10.21101/cejph.a6807

Objective: Prostate adenocarcinoma (CaP) is one of the most common malignancies in men in Slovakia and in the world. The disease accounts for more than 22% of all tumors in the male population. Screening studies show an increase in the diagnosis of CaP without improvement in overall or CaP-specific mortality. The main goal of the work is to evaluate the incidence of CaP in the group of patients examined and treated during the period from 2014 to 2019 at the urological outpatient clinic of the Railway Hospital (RH) in Košice, and to evaluate the risks and treatment options. Methods: Men aged 40 to 75 years underwent a preventive examination in 2014-2019 at the urology outpatient clinic, RH Košice. The number of screened patients was 3,943. Epidemiological parameter, diagnosis-related examinations (prostate specific antigen - PSA examination, digital rectal examination, and ultrasonography examination) as well as the frequency of examinations were monitored during the specified period on the basis of documentation. The number of prostate biopsies, incidence of prostate cancer and relation to PSA values were also monitored, as well as the classification of prostate cancers according to the degree of risk. Initial treatment in individual patients was also evaluated. Results: PSA values in patients who underwent biopsy ranged from 3.6 ng/mL to 2,000 ng/mL. We observed positive digital rectal examination in 52 patients. Of the number of patients examined, 231 (61.28%) were positive biopsies. There were negative biopsies with the finding of benign prostatic hyperplasia in 92 patients or chronic prostatitis in 54 patients, i.e., 146 (38.72%). According to the criteria for risk assessment based on the PSA value and the result of the histological examination, we diagnosed 109 low-risk patients, 57 medium-risk patients and 24 high-risk patients. Conclusion: CaP is detected by prevention about 10 years before it develops clinically. The main aim of preventive examinations should be to detect, in particular, high-risk forms of early-stage prostate cancer and to improve the quality of life of men. Due to the results of extensive studies, it is necessary to continue the active search for prostate cancer. This reduces the risk of metastatic forms of CaP.